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INTRODUCTION
We are interested in defining the genetic changes that initiate and drive the aggressive behavior of epithelial ovarian malignancies. In a pilot study looking at the genetic changes occurring across the whole genome of high-grade papillary serous ovarian cancers, we identified cyclin E as an interesting candidate gene. We found high-copy number amplification of the cyclin E gene locus to be the single most notable recurrent genetic event. Furthermore, epidemiological evidence links the subset of cyclin E overexpressing epithelial ovarian cancers to an increased number of lifetime ovulatory cycles and the "incessant ovulation" theory of ovarian cancer causality. Experimental systems have shown deregulation of cyclin E levels to result in chromosomal instability, a hallmark feature of epithelial ovarian cancers. This led us to hypothesize that cyclin E deregulation is an important initial event in ovarian carcinogenesis. We proposed three specific aims: (1) to characterize the genetic events induced along with cyclin E amplification and overexpression; (2) to determine the role of cyclin E and its collaborating genetic events in ovarian cancer initiation; and (3) to define the subset of ovarian cancers with impaired cyclin E inhibition and to determine whether these tumors demonstrate an enhanced response to targeted therapy. Here, we report research accomplishments from the first year of the study.
BODY
Specific Aim 1: To characterize the genetic events induced along with cyclin E amplification and overexpression.
Task 1: DNA analysis for genetic events occurring with cyclin E gene amplification using anatomical samples.
Upon screening 72 ovarian cancer cases on a frozen tumor tissue microarray for CCNE1 gene amplification using fluorescence in-situ hybridization (FISH), we identified 11 cases with a cluster pattern of cyclin E. These samples have also undergone gene expression profiling on an Agilent Human 1A VS Chip. Together, these studies have found a high correlation between cyclin E gene amplification and cyclin E overexpression. We planned to have these 11 samples arrayed with the Affymetrix 250K Nsp oligonucleotide microarray to determine the genetic events that occur commonly among ovarian cancer samples with CCNE1 gene amplification. However, we have put this task on hold for now as our collaborator has generated Agilent array CGH data on 128 ovarian cancer samples from our tumor bank. Of these, 20 tumors demonstrated focal amplification of the CCNE1 gene locus. We will be working together in the next year to determine the genetic copy number variation events that occur in this subset of 20 tumors.
We plan to take this analysis a step further with FISH analysis of formalin-fixed, paraffin-embedded tissue from the 132 papillary serous ovarian cancers in the gene expression dataset that were not analyzed by array CGH. This will allow us to correlate CCNE1 gene amplification and cyclin E expression patterns. We will be able to further refine our analysis by limiting the correlations to those tumors with CCNE1 gene amplification. Cases with normal CCNE1 gene copy number but high levels of cyclin E gene expression can be analyzed in a separate analysis. Differences in gene expression patterns between the two subsets of cyclin-E overexpressing tumors can also be analyzed.
Bacterial artificial chromosome (BAC) clone RPCI11.C-345J21 (Invitrogen, Carlsbad, CA) will be used as the FISH probe. Briefly, slide sections will be deparaffinized, treated with a protease solution, denatured, and hybridized overnight with the fluorescently-labeled FISH probe. The sections will then be washed and analyzed by fluorescence microscopy to detect cyclin E amplification. The results obtained from FISH experiments will be analyzed along with the corresponding gene expression profiling data from these same samples. Such analyses will allow for correlative studies between cyclin E amplification and other genes which are concurrently upregulated or down-regulated.
Task 2: RNA analysis for gene pathways activated with cyclin E overexpression, using anatomical samples.
We have completed RNA isolation and gene expression profiling from 132 papillary serous ovarian cancer samples. We have performed an analysis to identify the genes that are upregulated with cyclin E overexpression. We found the majority of the genes are cell cycle genes functionally related to cyclin E and cell cycle progression. This is unlike Her2 in breast cancer, where the genes correlating with HER2 are located on the same amplicon. However, we found some correlated genes adjacent to CCNE1, including C19orf1, C19orf12 and ZNF587.
Specific Aim 2: To determine the role of cyclin E and its collaborating genetic events in ovarian cancer initiation Task 3: Mouse model to test ability of cyclin E and its collaborating genetic events to induce oncogenic activation
To test the cancer initiating potential of cyclin E overexpression, we will use a mouse model which allows for introduction of collaborating genetic events to lead to transformation of mouse primary ovarian surface epithelial cells. Full-length cyclin E and two truncated cyclin E isoforms will be expressed by a retroviral vector which is able to introduce a gene of interest into a specific cell type or tissue.
Lower molecular weight isoforms of cyclin E have been described by Dr. K. Keyomarsi's group in Texas [1] . As many as five low molecular weight (LMW) isoforms of cyclin E exist in cancer tissues, while only the 50-kDa cyclin E form is expressed in normal tissues. The LMW isoforms have been described to have greater malignant potential.
Cyclin E overexpression:
We are creating the reagents that will allow for introduction of the full-length cyclin E gene and two truncated cyclin E isoforms into our mouse model. OVCAR5 cells were transfected with 2 µg pRC-CMV-cyclin E, pcDNA3-cyclin E FL, pcDNA3-cyclin E trunc 1, or pcDNA3-cyclin E trunc 2 using the BioT transfection reagent (Bioland Scientific, La Palma, CA). Whole cell lysates were collected and 25 µg of protein was analyzed by Western blot. Cyclin E protein expression was detected using an anti-cyclin E mouse monoclonal antibody (clone HE12, Santa Cruz Biotechnology, Santa Cruz, CA), followed by a fluorescentlyconjugated secondary antibody for visualization using the LI-COR Odyssey Infrared Imaging System (LI-COR Biotechnology, Lincoln, NB). The pRC-CMV-cyclin E construct was kindly provided by B. Weinberg and the pcDNA3-cyclin E constructs were provided by K. Keyomarsi (University of Texas).
Whole cell lysates were collected and the protein analyzed by Western blot (Fig. 1) . The pRC-CMV-cyclin E construct expressed full-length cyclin E (50 kDa) in addition to the lower molecular weight isoforms (45 kDa, 35 kDa). The pcDNA3-cyclin E FL also expressed all isoforms, especially the 50 kDa protein. The pcDNA3-cyclin E trunk 1 and trunk 2 expressed the 45 and 35 kDa isoforms, respectively. The cyclin E expression cassettes from these constructs will be recombined into the RCAS retroviral vector for introduction of the viral vector into our mouse model. Recombination Reaction with RCAS Vector: To test the cancer initiating potential of cyclin E overexpression using a mouse model, we will express full-length and truncated cyclin E isoforms from a retroviral vector called RCAS (replicationcompetent ASLV long terminal repeat with splice acceptor). The Gateway Technology system (Invitrogen, Carlsbad, CA) will be used for recombination of cyclin E into the RCAS vector (contains attR recombination sites). First, the cyclin E expression cassettes from the constructs mentioned above will be cloned into a donor vector, generating an entry clone with attL recombination sites. The LR reaction, which facilitates recombination of an attL substrate (entry clone) with an attR substrate (destination clone) in the presence of the LR clonase enzyme, will be performed for generating RCAS-cyclin E (Fig. 2) . Cyclin E will replace the lethal ccdB gene present in the parental destination vector. Mouse Model: We are in process of crossing transgenic mice that express Keratin5-TVA (chicken retroviral keratin receptor that is expressed on the ovary) with conditional P53 mutant mice. K5-TVA mice have been crossed with 129S4-Trp53 tm2Tyj (P53 LSL R172H) mice, which carry a conditional point-mutant allele of the p53 gene that can be activated by Cre-mediated recombination. This line contains a LoxP site and a transcriptional / translational STOP sequence in intron 1 (making it functionally equivalent to a null mutation) and an R172H missense mutation in exon 5. The strain was maintained on a 129S4/SvJae background. Activation with Cre-recombinase leads to deletion of the transcriptional termination sequence (Lox-Stop-Lox) and expression of the oncogenic P53 protein. The genotyping strategy is illustrated in figure 3 .
Primers:
Product Sizes: T036 : 5'-agc tag cca cca tgg ctt gag taa gtc tgc a -3' T036/T035: 279 bp (Mut LSL) T035 : 5'-ctt gga gac ata gcc aca ctg -3' T037/T035: 166 bp (Wild Type) T037 : 5'-tta cac atc cag cct ctg tgg -3' Figure 3 . Genotyping strategy of P53 LSL R172H mice. The noted primers allow us to detect the wild type allele with T037 and T035, which amplify intron 1, and the mutant allele with T036 and T035, which amplifies the LSL element.
We are genotyping mice with one-step PCR procedures using mouse tail tissues to isolate DNA from crude lysates. Mice that carry the K5-TVA transgene and the conditional mutant P53 allele will be selected for further experiments. The RCASCyclin E vector and Ad-Cre will be introduced into the OSE of K5-TVA p53 LSL R172H mice to determine the oncogenic potential of cyclin E overexpression in the setting of P53 deficiency. Experiments will be performed with the full length cyclin E construct as well as with the truncated cyclin E low molecular weight isoforms.
Specific Aim 3:
To define the subset of ovarian cancers with impaired cyclin E inhibition and to determine whether these tumors demonstrate an enhanced response to targeted therapy Task 4: Immunohistochemistry (IHC) for cyclin E, SKP2, P27 using anatomic samples
We will perform immunohistochemistry for cyclin E, SKP2 and P27 in patient ovarian cancer samples. This task will be performed in the upcoming year.
Task 5: DNA mutation analysis for FBXW7 mutations, using anatomical samples
In our pilot study, we identified thirteen samples with loss of heterozygosity at the FBXW7 gene locus. The SCF-Fbw7 ubiquitin ligase system ensures tight control of cyclin E levels. Disruption of the Fbw7 tumor suppressor leads to genetic instability through deregulated cyclin E activity. The FBXW7 gene has been found to be mutated in ovarian cancer cell lines, implicating its potential role in the pathogenesis of this malignancy. We planned to screen for mutations in the FBXW7 gene in these 13 ovarian cancer samples. We did a search of publically available data from Sanger and the cancer genome atlas (TCGA). In the Sanger data, one FBXW7 mutation (c.1417delA) was found in a single cell line (T-24) among a panel of 21 ovarian cancer cell lines. Sanger data also included sequencing in 183 clinical tumors (including breast, CNS, kidney, colon, lung, pancreas, pleura, salivary gland, skin, upper GI tract, and urinary tract) and found mutations in FBXW7 in 2 (1%) of samples. No clinical ovarian cancer samples were included in the Sanger data, but the TCGA used NextGen sequencing and found no FBXW7 mutations in 60 to 80 ovarian cancer samples. Based on this publically available data, FBXW7 appears to be very infrequently mutated in multiple tumor types, including ovarian cancer. Therefore, we have not performed this task and have focused our attention on other areas that are likely to be of higher yield.
Task 6: In vitro proliferation assays, using 6 serous ovarian cancer cell lines with various cyclin E and SKP2 expression, and assessing for therapeutic response to the proteasome inhibitor, bortezomib
The majority of our work over the last year in specific aim 3 was spent addressing this task. The goal of this task was to determine whether targeted therapies could be used to specifically inhibit ovarian cancers that overexpress cyclin E.
To accomplish this task, we assayed a panel of ovarian cancer cell lines to determine endogenous levels of cyclin E and SKP2. We found OVCAR3 cells to express high levels of both proteins and OVCAR5 cell to express low levels of both proteins (figure 4
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CycE mRNA expression normalized to GAPDH (CWM method) Tumors with cyclin E deregulation were hypothesized to be attractive targets for therapy with SKP2 inhibitors. SKP2 is a ubiquitin ligase that targets P27kip1 for degradation. P27 is a powerful negative regulator of the cell cycle, preventing activation of cyclin E-cdk2 or cyclin D-cdk4 complexes and cell cycle progression at the G1 to S boundary. Therefore, inhibition of SKP2 could lead to upregulation of P27 levels and inhibition of aberrant cyclin E activity and inhibition of progression through the cell cycle. Recently, the proteasome inhibitor bortezomib (Velcade) was shown to inhibit the growth of colorectal tumor cell lines through upregulation of P27 and induction of apoptosis.
We tested the sensitivity of OVCAR3 and OVCAR5 ovarian cancer cell lines to the effects of bortezomib. Consistent with our hypothesis, we discovered that the cyclin E overexpressing OVCAR3 cells were indeed more sensitive to bortezomib (figure 6). However, given the fact that OVCAR3 and OVCAR5 cells differ in many ways other than cyclin E levels, we set out to create a more informative model system. We transfected OVCAR5 cells to overexpress cyclin E or an empty control vector. We treated these cells with bortezomib and found no difference in their response ( figure 7 ). Similar negative data were obtained with stable transfection in OVCAR5 cells, as well as with overexpression of cyclin E in other ovarian cancer cell lines such as SKPV3 and A2780 (data not shown). This led us to conclude that the differential effects demonstrated between OVCAR3 and OVCAR5 were not due to cyclin E levels. In light of this data disproving our original hypothesis, we searched the literature for alternative agents that might be capable of differentially targeting cyclin E overexpressing cells. We found a report of a natural dietary phytochemical, indole-3-carbinole (I3C), that works as a natural elastase inhibitor and disrupts cyclin E activity [2] . The low molecular weight (LMW) isoforms of cyclin E are tumor-specific and cause increased cell proliferation, elevated kinase activity and increased clonogenicity. These LMW cyclin E isoforms are generated via proteolysis of the normal 50 kDa cyclin E form by the elastase enzyme, which itself can be selectively inhibited by I3C. I3C exhibits potent anti-carcinogenic properties and has been shown to shift the accumulation of cyclin E from the LMW to the 50 kDa isoform and to induce a G1 cell cycle arrest.
Considering the specific inhibitory properties of I3C and bortezomib in the processing and expression of cyclin E, we investigated the hypothesis that ovarian cancer overexpressing cyclin E may demonstrate an enhanced response to targeted combination therapy with I3C and bortezomib. We found synergistic cytotoxicity of I3C and bortezomib in both OVCAR3 and OVCAR5 cells, with greater sensitivity of each individual drug in OVCAR3 cells and greater synergistic effect of the drug combination in OVCAR5 cells (figure 8). We found that I3C and bortezomib have varying effects on the cell cycle in the two different cell lines (figure 9). I3C induces an S phase accumulation in OVCAR3 and a G1 arrest in OVCAR5 cells. Bortezomib induces a G2/M arrest in both cell lines, but this is more pronounced in the OVCAR5 cells. The combination of the two drugs causes a G2/M arrest and the accumulation of a sub-G1 population of cells that are undergoing apoptosis. We performed western blotting analysis for proteins from various cellular pathways to interrogate the mechanisms for the observed data. We found a decrease in phospho-Rb levels with increasing drug concentration in both cell lines for single and combination treatment, with the effect being more pronounced in the OVCAR5 cells ( figure 11 ). This data suggest an inhibitory effect of the drugs on progression through the cell cycle at the G1/S phase. P27kip1 levels are not altered and do not appear to be responsible for the observed effects. Western blotting data for additional proteins representing additional pathways are currently underway. This data have particular relevance in light of recent phase II data demonstrating limited single-agent activity of bortezomib in recurrent ovarian cancer [3] . The finding that I3C, a natural dietary phytochemical found in cruciferous vegetables, synergistically sensitizes ovarian cancer cells to the cytotoxic effects of bortezomib may lead to a novel therapeutic combination.
Task 7: siRNA experiments against cyclin E and SKP2 using ovarian cancer cell lines that overexpress both proteins Small interfering RNAs (siRNAs) against cyclin E and SKP2 were purchased from Sigma Aldrich and introduced into the OVCAR3 cell line (which expressed high endogenous levels of cyclin E and SKP2). We were able to achieve partial knockdown of protein expression levels of the two targets ( figure 12 ). However, we found the cells with cyclin E knock-down to grow poorly and to be a poor experimental system for further manipulation, such as treatment with drugs. Furthermore, we were initially interested in SKP2 as a target for inhibition in tumors that overexpress cyclin E. Based on the negative data generated in task 6 (no difference in cell proliferation in cells expressing different levels of cyclin E when treated with the proteasome inhibitor bortezomib) and the generation of only partial knock-down of SKP2 levels, we did not pursue further experiments with these cells. 
Task 8: in vivo tumor xenograft experiments
In vivo tumor xenograft experiments have not yet begun.
Task 9: Data analysis and manuscript generation and grant preparation
Data analysis has been on-going throughout the year and has driven the experimental processes, with re-evaluation of hypotheses and generation of additional experiments to address the evolving data. Data from specific aim 3 were presented in poster format at the 2010 AACR meeting in Washington D.C. (see appendix). A manuscript is currently being generated with this data and will be submitted for publication in the next month. Furthermore, a review article on ovarian cancer biomarkers was published during this year by myself and a mentor on this award, Beth Karlan (see appendix) [4] . Dr. Karlan provided me with the opportunity to write this review to further support my academic and career development activities related to ovarian cancer research.
KEY RESEARCH ACCOMPLISHMENTS
 We found synergistic cytotoxicity of I3C and bortezomib in ovarian cancer cell lines with differing levels of cyclin E expression. These findings provide a potential novel therapeutic option in the treatment of ovarian cancer expressing high or low levels of cyclin E. This may have particular clinical relevance in light of recent phase II clinical data showing limited activity of bortezomib as a single-agent in recurrent ovarian or peritoneal carcinomas.  We have generated a cross between K5-TVA transgenic mice and P53 conditional mutant mice that will be the basis for our on-going work in specific aim 2.  We examined gene expression profiles among cyclin E overexpressing ovarian cancers and found the co-expressed genes to be drivers of the cell cycle rather than neighboring genes on the CCNE1 gene locus.
REPORTABLE OUTCOMES
 Taylor 
CONCLUSION
At the genetic level, ovarian cancer is characterized by a large degree of genetic instability. High copy-number amplification at the CCNE1 (cyclin E) gene locus is the single most notable recurrent change, occurring in about 20% of tumors. We have hypothesized that CCNE1 gene amplification is an initiating event in the carcinogenic process of a subset of epithelial ovarian cancers. We have further hypothesized that this subset of tumors can be treated with specific targeted therapies, based on the biology of cyclin E overexpression. In the first year of this award, we have made progress towards testing our hypothesis of cyclin E-induced ovarian cancer initiation in a mouse model. We have successfully crossed the K5-TVA mice with P53 conditional mutant mice to generate the model for introduction of genetic changes to ovarian surface epithelial cells. We are in the process of constructing the vectors to introduce full-length cyclin E, truncated low molecular weight cyclin E, and other collaborating genetic events to the mouse model. In testing for a targeted response of cyclin Eoverexpressing cells, we have demonstrated that the proteasome inhibitor bortezomib does not affect ovarian cancer cells through a cyclin E-mediated pathway. However, based on the biology of low molecular weight cyclin E isoforms, we found a natural dietary phytochemical called Indole-3-Carbinol (I3C) that disrupts cyclin E processing through the inhibition of the elastase enzyme. When combining I3C with bortezomib, we found I3C to synergistically sensitize ovarian cancer cells to bortezomib. This finding has translational potential as bortezomib as a single-agent was found to have minimal activity in a phase II treatment trial of recurrent ovarian cancer. This finding could re-introduce bortezomib to the therapeutic armamentarium against ovarian cancer if the in vitro results replicate in mice and humans.
In the upcoming two years of the grant, we look forward to examining the potential ovarian cancer initiating effects of cyclin E overexpression in ovarian surface epithelial cells with our mouse model. We will also examine and describe the genetic events that occur commonly among cyclin E overexpressing clinical ovarian cancer samples and look for clues to the biology underlying these tumors. We will further our work in looking for targeted therapies to treat this subset of epithelial ovarian cancers. Epithelial ovarian cancer (EOC) remains the leading cause of gynecologic cancer mortality. Cyclin E deregulation is an important initial event in a subset of EOCs associated with poor outcome. The proteasome inhibitor bortezomib has been shown to inhibit the growth of both ovarian and colorectal tumor cell lines through upregulation of p27, indicating its potential therapeutic role in the subset of ovarian cancers that overexpress cyclin E. As many as five low molecular weight (LMW) isoforms of cyclin E exist in cancer tissues, while only the 50-kDa cyclin E form is expressed in normal tissues. These LMW isoforms are generated via proteolysis of the normal 50-kDa cyclin E form by elastase. Proteolytic activity of elastase can be selectively inhibited by indole-3-carbinol (I3C), a natural component of Brassica vegetables and potent anticarcinogen. Considering the specific inhibitory properties of I3C and bortezomib in the processing and potential expression of cyclin E, respectively, we hypothesize that ovarian cancers overexpressing cyclin E may demonstrate an enhanced response to targeted combination therapy with I3C and bortezomib.
Results

Methods
Viability of OVCAR3 and OVCAR5 human ovarian cancer cells ± I3C and ± bortezomib for 48 h was assessed by MTT assays.
Synergy between I3C and bortezomib was determined using isobologram analysis using Calcusyn software; combination indices (CI)<1.0 are considered synergistic.
FACS analysis of Annexin V and propidium iodide (PI) stained cells was used to discriminate between early and late apoptosis in OVCAR3 and OVCAR5 cells treated with ± I3C and ± bortezomib for 24 h.
Western blotting was used for protein expression analysis of OVCAR3 and OVCAR5 cells treated with ± I3C and ± bortezomib for 24 h.
Real-time PCR was used for gene expression analysis.
Our data demonstrate synergistic cytotoxicity of I3C and bortezomib, through premature apoptosis and impairment of cell cycle progression. Our findings support a possible therapeutic role for I3C and bortezomib in the treatment of ovarian cancers expressing high or low levels of cyclin E.
Translational Potential 
